Ovarian cancer vaccine shows promising results in human study
The survival rate of ovarian cancer in early stages is pretty high: Up to 70% for stage II.
However, late stages (III and IV) have a dramatically low survival rate as low as %39 and %17.
Immunotherapy has gained ground against a stubborn opponent: ovarian cancer.
A personalized cancer vaccine is safe and may lengthen the lives of ovarian cancer patients, a small clinical trial found.
A vaccine, then, might be able to trigger and boost the immune system and increase the survival rates of patients, said Dr. Lana Kandalaft, senior author of the new study and an adjunct assistant professor at the University of Pennsylvania Perelman School of Medicine.
Overall two-year survival was highest among responsive study patients who received the vaccine and two chemo drugs: Seventy-eight percent of vaccinated patients who also received the chemo drugs survived two years, compared with just 44% of patients who received the drugs but no vaccine. You may find the full article in the following reference.
Pic ref: http://ovarian.org/about-ovarian-cancer/what-are-the-signs-a-symptoms
News ref: https://edition.cnn.com/2018/04/11/health/ovarian-cancer-vaccine-study/index.html
